Wall Street analysts expect Lantheus Holdings Inc (NASDAQ:LNTH) to report $78.45 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Lantheus’ earnings. The lowest sales estimate is $77.40 million and the highest is $79.50 million. Lantheus reported sales of $74.35 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.5%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, February 20th.
According to Zacks, analysts expect that Lantheus will report full year sales of $78.45 million for the current financial year, with estimates ranging from $324.90 million to $327.50 million. For the next year, analysts anticipate that the business will post sales of $349.55 million per share, with estimates ranging from $348.80 million to $350.30 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Lantheus.
Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.04. Lantheus had a negative return on equity of 46.45% and a net margin of 9.59%. The firm had revenue of $79.94 million during the quarter, compared to analyst estimates of $77.18 million. During the same period in the previous year, the company posted $0.15 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis.
Lantheus (LNTH) traded up $0.10 during mid-day trading on Thursday, hitting $20.60. 330,400 shares of the stock traded hands, compared to its average volume of 545,248. Lantheus has a 1 year low of $7.95 and a 1 year high of $24.10. The stock has a market capitalization of $768.87, a price-to-earnings ratio of 18.30, a price-to-earnings-growth ratio of 1.63 and a beta of 0.94. The company has a quick ratio of 2.46, a current ratio of 2.96 and a debt-to-equity ratio of -3.41.
In other news, insider Michael P. Duffy sold 11,917 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $21.63, for a total transaction of $257,764.71. Following the completion of the sale, the insider now owns 152,301 shares of the company’s stock, valued at $3,294,270.63. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Timothy G. Healey sold 11,314 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $21.51, for a total transaction of $243,364.14. The disclosure for this sale can be found here. Insiders have sold 29,986 shares of company stock worth $625,488 in the last quarter. Insiders own 2.30% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in LNTH. Thrivent Financial For Lutherans bought a new position in Lantheus in the second quarter valued at approximately $321,000. Royce & Associates LP purchased a new position in shares of Lantheus during the second quarter worth $4,896,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Lantheus during the second quarter worth $770,000. QS Investors LLC acquired a new stake in Lantheus during the second quarter valued at $2,256,000. Finally, Prudential Financial Inc. acquired a new stake in Lantheus during the second quarter valued at $835,000. 91.95% of the stock is owned by hedge funds and other institutional investors.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.